Peptides

Myostatin decoy receptor that showed early promise in muscular dystrophy trials, then got shut down over vascular side effects.

Proapoptotic peptide that kills off adipose-tissue blood vessels; pulled from development after it damaged kidneys in human trials.

Topical copper tripeptide marketed for hair follicle stimulation, distinct from (and less studied than) GHK-Cu.

A growth hormone fragment engineered to isolate the fat-burning effect and drop HGH's blood sugar and tissue growth effects. Trialed for obesity, never reached market.

A non-hematopoietic EPO fragment developed for neuropathic pain and small-fiber nerve repair, without EPO's blood-thickening effects.

A 15-amino-acid fragment of the gastric body-protection compound, the most widely self-administered healing peptide for tendon, ligament, muscle, and gut injuries.

Organ-targeted bioregulator from the Khavinson lineage, aimed at bronchial and respiratory tissue.

Organ-targeted bioregulator from the Khavinson lineage aimed at cardiac tissue repair.

Organ-targeted Khavinson peptide aimed at cartilage and joint tissue regeneration.

Porcine neuropeptide preparation with clinical use for stroke and dementia in non-US countries.

Organ-targeted peptide for bronchial and pulmonary tissue support.

Common combination vial pairing a GHRH analogue with a GH secretagogue. Sold premixed.

A modified GHRH analog for boosting growth hormone release, almost always stacked with a GHRP like Ipamorelin. The 'without DAC' version (Mod-GRF) sees far more use than the long-acting DAC version.

Long-acting GHRH analog with week-long half-life via albumin binding; distinct from daily-dosing CJC-1295.

Organ-targeted Khavinson peptide aimed at cerebral cortex structure and cognitive function.

Organ-targeted Khavinson peptide aimed at immune activation and B-cell function.

A neuropeptide showing regenerative effects in animal models of Alzheimer's and neurological injury, with no human trials.

A short peptide first isolated from the brains of sleeping rabbits, explored for sleep, stress and pain modulation. Human evidence for an actual sleep-inducing effect is thin, despite the name.

A synthetic tetrapeptide based on a natural pineal-gland extract, studied by Russian researchers for telomerase activation, sleep and immune aging.

A 15-amino-acid fragment of the neural cell adhesion molecule that activates FGFR1 in rodent brains — real synaptic-plasticity data, zero human trials.

Senolytic peptide that disrupts the FOXO4-p53 interaction to induce selective apoptosis of senescent cells. Highly promising in mouse models, with minimal human evidence.

A naturally occurring copper-binding tripeptide found in human plasma. The best-studied skin peptide, also investigated for wound healing, hair and connective tissue.

Potent synthetic growth hormone secretagogue with strong GH stimulation and emerging research support for tissue repair.

Potent GH secretagogue with distinctive strong appetite stimulation via ghrelin receptor mimicry.

The body's main intracellular antioxidant tripeptide; oral supplementation genuinely raises body stores in trials, but the skin-lightening and detox claims built on top of that are much thinner.

GnRH agonist peptide that stimulates endogenous LH and FSH to preserve testicular function and fertility during testosterone replacement therapy.

Potent dual-receptor GH secretagogue with cardioprotective properties, limited by rapid receptor desensitization.

A mitochondrial-derived peptide originally discovered for neuroprotection against Alzheimer's-related cell death, now explored in metabolic and longevity research.

A modified, long-acting version of IGF-1, the growth factor downstream of growth hormone that directly drives muscle cell proliferation. Used in bodybuilding circles for localized and systemic muscle growth.

One of the most selective growth hormone secretagogues available. It stimulates GH release without the cortisol, prolactin or appetite spikes of older GHRPs, and is almost always paired with a GHRH analog like CJC-1295/Mod-GRF.

The master upstream regulator of the reproductive hormone axis, more recently studied for direct effects on sexual and emotional brain processing, not just downstream hormone levels.

Upstream regulator of GnRH release, studied in reproductive endocrinology.

A tiny 3-amino-acid fragment of alpha-MSH studied mainly for gut and skin inflammation, popular among self-experimenters with IBD-type symptoms.

A stabilized enkephalin fragment marketed as a topical, needle-free alternative to neuromuscular-blocking wrinkle treatments — the mechanism is plausible, the human wrinkle-reduction evidence is thin.

Organ-targeted peptide bioregulator designed to support liver tissue repair and hepatic function.

Endogenous antimicrobial and immunomodulatory peptide with evidence for topical wound healing and emerging systemic applications.

Lipidated collagen-mimetic peptide (palmitoyl-KTTKS) that pushes fibroblasts to make more collagen and glycosaminoglycans.

FDA- and EU-approved MC1R agonist for erythropoietic protoporphyria; regulated pharmaceutical with photoprotection benefits, distinct from unregulated MT-2.

Unregulated synthetic melanocortin agonist used illicitly for tanning and erectile function, with significant cardiovascular and melanoma safety concerns.

An endogenous five-amino-acid opioid that quietly puts a brake on cell division — well-studied in oncology and immunology labs, but that's not the same as a validated self-use protocol.

Muscle-specific IGF-1 isoform generated by mechanical stress; promotes local muscle repair and satellite cell activation.

Mitochondrial-derived peptide encoded in mitochondrial DNA, studied for metabolic regulation and exercise-mimetic effects.

Organ-targeted peptide supporting ovarian tissue function and reproductive health.

CNTF-derived peptide with claimed neurogenic potential; adamantane-conjugated variant designed for blood-brain barrier penetration.

Organ-targeted peptide bioregulator designed to support pancreatic function and glucose metabolism.

Engineered spadin analog with improved TREK-1 channel inhibition and fast-acting antidepressant properties.

Native MGF with a polyethylene glycol tag bolted on to stretch its otherwise minutes-long half-life into something injectable a few times a week; the underlying human data is essentially borrowed from other pegylated IGF-1 work, not PEG-MGF itself.

Pineal-derived peptide bioregulator with cognitive and neuroprotective positioning.

CANCER RESEARCH ONLY: p53-derived peptide inducing tumor cell necrosis through HDM-2 interaction; no human clinical trials, and no longevity or anti-aging protocol exists.

Organ-targeted peptide bioregulator designed to support prostate tissue structure and urogenital function.

A melanocortin-receptor agonist that acts on the brain's sexual-arousal pathways rather than on blood flow directly — FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women, used off-label by men for erectile/libido support.

Preclinical peptide that blocks a Wnt-pathway inhibitor (CXXC5) in hair follicles, designed to restore hair regrowth through molecular disinhibition.

Investigational triple-hormone-receptor agonist with the largest weight-loss effect of any GLP-1-class compound tested so far. Not FDA-approved.

Russian-developed anxiolytic peptide, approved as a prescription drug in Russia for anxiety and mixed anxiety-depressive disorders. Used off-label elsewhere as a calming nasal-spray nootropic.

Long-acting GLP-1 receptor agonist that kicked off the modern GLP-1 weight-loss era. FDA-approved for type 2 diabetes and chronic weight management.

Russian-developed nootropic peptide, approved as a prescription drug in Russia for stroke recovery and cognitive/attention support. Widely used off-label elsewhere as a nasal-spray nootropic.

The original, FDA-approved GHRH analog (its approved brand was later discontinued), the natural-sequence precursor that CJC-1295/Mod-GRF are modified versions of.

A rodent-only 'exercise in a pill' compound that genuinely turns on exercise-like gene programs — but it is a small molecule, not a peptide, and has never been dosed in a human trial.

Topical cosmetic peptide marketed as a non-invasive alternative to Botox for expression lines.

Mitochondria-targeted tetrapeptide that stabilizes cardiolipin and restores oxidative phosphorylation. FDA-approved for rare Barth syndrome, investigational in heart failure and aging-related conditions.

Synthetic fragment of thymosin beta-4 studied preclinically for tissue repair.

A naturally occurring wound-response peptide released by platelets, used for muscle, tendon and neurological healing, often stacked with BPC-157.

FDA-approved GHRH analog specifically approved for reducing visceral fat in HIV-associated lipodystrophy, used off-label more broadly for visceral fat reduction and as a growth-hormone secretagogue.

Testis-targeted bioregulator peptide from the Khavinson family, proposed for testicular and vascular function.

Thymic bioregulator from the Khavinson family with long-term human mortality follow-up and immune-modulating effects.

A naturally occurring immune-regulating peptide, approved as a prescription drug (Zadaxin) in dozens of countries for chronic hepatitis B/C and as an immune adjuvant, one of the few peptides here with real regulatory approval somewhere in the world.

A dual GIP/GLP-1 receptor agonist that generally outperforms semaglutide for weight loss in head-to-head trials. FDA-approved for type 2 diabetes and chronic weight management.

Organ-targeted peptide supporting vascular endothelial cell function and tissue regeneration.

Short-form thymic dipeptide bioregulator with immunomodulatory and T-cell differentiation effects.

Endogenous neuropeptide and vasodilator with immunomodulatory properties, used investigationally for mold-illness immune dysregulation and pulmonary hypertension.

A zinc-dependent thymic hormone with real, decades-old immunology behind it, repackaged for topical hair-loss use on evidence that is mostly adjacent, not direct.